Methods for predicting risk of interstitial pneumonia
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
University of Colorado Colorado Springs
Member
SteriTools, LLCSteriTools is developing a De Novo intraoperative device meant to kill bacteria at point of use as part of the normal operating room workflow. Preliminary GLP tests yield a 7-8 log reduction of eight of the major SSI producing microbes in just 15 seconds.
SteriTools is developing a De Novo intraoperative device meant to kill bacteria at point of use as part of the normal operating room workflow. Preliminary GLP tests yield a 7-8 log reduction of eight of the major SSI producing microbes in just 15 seconds.
Publication Number
US-12774494-B2
Publication Date
2026-10-27
Expiration Date
Abstract
Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.
Core Innovation
The disclosed methods detect an A allele of an rs3778337 SNP, a C allele of an rs10484326 SNP in a DSP gene, or a combination thereof, in a biological sample from a subject having interstitial lung disease. Genome-wide association data identify these DSP loci as associated with disease risk, with rs10484326 exhibiting an odds ratio of 0.78. Lung tissue analysis reveals elevated DSP expression in cases compared to controls, varying by rs2076295 genotype.
A further method detects the specified DSP SNP alleles in combination with a first level of DSP gene expression. These genetic and expression markers facilitate assessing interstitial lung disease risk, prognosis, and progression. The disclosure also describes broader SNP and gene-expression panels as well as serial measurements to monitor disease status or treatment response.
Claims Coverage
The independent claims comprise two claims directed to detecting DSP SNP alleles in a biological sample from a subject having interstitial lung disease, with one claim additionally covering detection of DSP expression, reflecting two inventive features.
Detection of specified DSP gene SNP alleles
The claim covers detecting an A allele of an rs3778337 SNP in a DSP gene, a C allele of an rs10484326 SNP in a DSP gene, or a combination thereof, in a first biological sample obtained from a subject having interstitial lung disease.
Detection of DSP gene SNP alleles and expression
The claim covers detecting an A allele of an rs3778337 SNP in a DSP gene, a C allele of an rs10484326 SNP in a DSP gene, or a combination thereof, and a first level of DSP gene expression in a first biological sample obtained from a subject having interstitial lung disease.
The independent claims cover detection of one or both specified DSP gene SNP alleles in a sample from a subject with interstitial lung disease, with the second independent claim additionally requiring detection of a DSP gene expression level.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Detection of specified DSP SNP alleles in a biological sample, including blood, from a subject having interstitial lung disease, such as idiopathic pulmonary fibrosis, familial interstitial pneumonia, and idiopathic interstitial pneumonia.
Detection of specified DSP SNP alleles together with a DSP gene expression level in a biological sample from a subject having interstitial lung disease.
Assessing interstitial lung disease risk, prognosis, and progression using genetic-marker methods.
Monitoring interstitial lung disease or treatment response through serial measurements in subjects undergoing treatment.
Interested in licensing this patent?